Phone
EmailPhoneEmail
HemoShear Therapeutics
Business Services · Virginia, United States · <25 Employees
View Company Info for Free
About
Headquarters
501 Locust Ave Ste 301, Charlottesville, Virgin...Phone Number
(434) 872-0196Website
www.hemoshear.comRevenue
$6.5 MillionIndustry
Who is HemoShear Therapeutics
HemoShear Therapeutics is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patientneed. HemoShear's drug discovery platform, REVEAL-Tx, enables the Company's scientists to create best-in-class, biologically relevant human disease models to uncover underlying mechanisms of disease, translate those discoveries into drug targets, and select candidates that may treat patients successfully. In addition to the Company's proprietary rare disease programs, HemoShear has exclusive partnerships to identify novel therapeutic approaches in nonalcoholic steatohepatitis (NASH) and an undisclosed rare liver disease with Takeda, and in gout with Horizon Therapeutics.Read more
Popular SearchesHemoShear Therapeutics IncHemoshear Therapeutics LLCHemoShear TherapeuticsHemoshearJm Proprietary LLCSIC Code 87,873NAICS Code 54,541Show moreHemoShear Therapeutics Org Chart
PhoneEmailPhoneEmailSimilar Companies to HemoShear Therapeutics
- <$5M
1
- 39<$5M
2
- <$5M
3
- $5.6M
4
- <$5M
5
- 32<$5M
6
HemoShear Therapeutics Tech Stack
A closer look at the technologies used by HemoShear Therapeutics
See more technologies
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
HemoShear Therapeutics News & Media
HemoShear Attends Piper Sandler Conference
CHARLOTTESVILLE, Va., May 18, 2023 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, participated in the Piper Sandler Spring Biopharma Symposium being held in Boston, MA, Wednesday, May 17 through Thursday, May 18, 2023. The HemoShear...May 18, 2023HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference
CHARLOTTESVILLE, Va., Nov. 17, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, today announced that Brain Wamhoff, Interim CEO, will present at the 34th Annual Piper Sandler Healthcare Conference being held November 29 – December 1...Nov 17, 2022HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect
CHARLOTTESVILLE, Oct. 18, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, today announced that it will participate in SVB Leerink Biopharma Private Company Connect being held virtually October 26-27. Investor one-on-one meetings...Oct 18, 2022HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline
Fifth Milestone Achieved by HemoShear with Novel Compounds for Second Target CHARLOTTESVILLE, Va., Sept. 21, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead...Sep 21, 2022HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
Industry Veteran Robert Gould, PhD, Steps up to Board Chair CHARLOTTESVILLE, Va., Aug. 25, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff, PhD, as interim chief...Aug 25, 2022
Read more news
Frequently Asked Questions regarding HemoShear Therapeutics
HemoShear Therapeutics is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need. HemoShear's drug discovery platform, REVEAL-Tx, enables the Company's scientists to create best-in-class, biologically relevant human disease models to uncover underlying mechanisms of disease, tr... Read More
